AbbVie Inc (ABBV)vsIRIDEX Corporation (IRIX)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
IRIX
IRIDEX Corporation
$1.03
0.00%
HEALTHCARE · Cap: $18.69M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 116008% more annual revenue ($61.16B vs $52.67M). ABBV leads profitability with a 6.9% profit margin vs -8.4%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
IRIX
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+82.1%
Fair Value
$8.00
Current Price
$1.03
$6.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
16.0% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -126.4% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : IRIX
The strongest argument for IRIX centers on PEG Ratio, Revenue Growth. Revenue growth of 16.0% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : IRIX
The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while IRIX is a growth play — different risk/reward profiles.
IRIX carries more volatility with a beta of 0.76 — expect wider price swings.
IRIX is growing revenue faster at 16.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 38/100). IRIX offers better value entry with a 82.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
IRIDEX Corporation
HEALTHCARE · MEDICAL DEVICES · USA
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?